title: The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.|b The Institute of Cancer Research , London , UK.
authors.forename: Priya
authors.initials: P
authors.lastname: Sriskandarajah
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.|b The Institute of Cancer Research , London , UK.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Pawlyn
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
authors.forename: Kabir
authors.initials: K
authors.lastname: Mohammed
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
authors.forename: Claire E
authors.initials: CE
authors.lastname: Dearden
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.|c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.|c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Boyd
authors.affiliation: a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.|b The Institute of Cancer Research , London , UK.
authors.forename: Martin F
authors.initials: MF
authors.lastname: Kaiser
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D012008:Recurrence; D019233:Retreatment; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide; C467566:pomalidomide